celecoxib and Invasiveness, Neoplasm studies

celecoxib and Invasiveness, Neoplasm

Research Excerpts

Excerpt	Relevance	Reference
"Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily."	9.15	Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011)
"Celecoxib, a selective cyclooxygenase‑2 inhibitor, has chemo‑preventive activity against different cancer types, including bladder cancer (BC)."	7.91	Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. ( Chen, L; Deng, W; Fu, B; Huang, M; Li, Y; Liu, X; Wang, G; Wang, Y; Wu, Y; Zeng, T; Zhou, X; Zhou, Z, 2019)
"Allyl isothiocyanate (AITC) occurs in cruciferous vegetables that are commonly consumed by humans and has been shown to inhibit urinary bladder cancer growth and progression in previous preclinical studies."	7.79	Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. ( Bhattacharya, A; Li, Y; Shi, Y; Zhang, Y, 2013)
"Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma."	7.78	Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012)
"The disparate molecular mechanisms of celecoxib-induced growth inhibition in human breast cancer cells depends upon the level of COX-2 expression and the invasive potential of the cell lines examined."	7.73	Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. ( Basu, GD; Gendler, SJ; Mukherjee, P; Pathangey, LB; Tinder, TL, 2005)
"A total of 64 invasive breast cancer patients were recruited in the N001 Phase II, multicenter, open-label, single-arm study to receive four cycles of FEC (500, 100, 500 mg/m(2)) followed by four cycles of T (100 mg/m(2)) with concurrent CXB (200 mg b."	6.78	Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. ( Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY, 2013)
"Celecoxib was well tolerated, with similar adverse events and quality-of-life in both arms."	6.76	A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. ( Czerniak, BA; De la Cerda, J; Eagle, C; Grossman, HB; Lee, JJ; Lerner, SP; Liu, S; Palmer, JL; Richmond, E; Sabichi, AL; Viner, JL, 2011)
"Triple negative breast cancers experience the highest pCR rate of 30%."	6.75	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. ( Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M, 2010)
"Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied."	5.40	Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014)
"Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies."	5.40	Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. ( Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J, 2014)
"Melanoma is the most serious type of skin disease and a leading cause of death from skin disease due to its highly metastatic ability."	5.37	Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. ( Katiyar, SK; Singh, T, 2011)
"Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily."	5.15	Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011)
"Epidemiologic studies suggest that long term low dose celecoxib use significantly lowers breast cancer risk."	5.13	Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. ( Chen, YC; Flynn, JT; Hewett, JE; Qin, W; Rottinghaus, G; Ruhlen, RL; Sauter, ER, 2008)
"Celecoxib, a selective cyclooxygenase‑2 inhibitor, has chemo‑preventive activity against different cancer types, including bladder cancer (BC)."	3.91	Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. ( Chen, L; Deng, W; Fu, B; Huang, M; Li, Y; Liu, X; Wang, G; Wang, Y; Wu, Y; Zeng, T; Zhou, X; Zhou, Z, 2019)
" We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity."	3.80	A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014)
"Allyl isothiocyanate (AITC) occurs in cruciferous vegetables that are commonly consumed by humans and has been shown to inhibit urinary bladder cancer growth and progression in previous preclinical studies."	3.79	Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. ( Bhattacharya, A; Li, Y; Shi, Y; Zhang, Y, 2013)
"Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma."	3.78	Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012)
"The disparate molecular mechanisms of celecoxib-induced growth inhibition in human breast cancer cells depends upon the level of COX-2 expression and the invasive potential of the cell lines examined."	3.73	Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. ( Basu, GD; Gendler, SJ; Mukherjee, P; Pathangey, LB; Tinder, TL, 2005)
"A total of 64 invasive breast cancer patients were recruited in the N001 Phase II, multicenter, open-label, single-arm study to receive four cycles of FEC (500, 100, 500 mg/m(2)) followed by four cycles of T (100 mg/m(2)) with concurrent CXB (200 mg b."	2.78	Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. ( Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY, 2013)
"Celecoxib was well tolerated, with similar adverse events and quality-of-life in both arms."	2.76	A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. ( Czerniak, BA; De la Cerda, J; Eagle, C; Grossman, HB; Lee, JJ; Lerner, SP; Liu, S; Palmer, JL; Richmond, E; Sabichi, AL; Viner, JL, 2011)
"Triple negative breast cancers experience the highest pCR rate of 30%."	2.75	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. ( Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M, 2010)
"Patients with advanced pancreatic cancer who had not received chemotherapy and had acceptable organ function were eligible for the study."	2.71	A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. ( Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ, 2005)
" Herein, we assessed a combination of chidamide plus celecoxib (called CC-01) combined with programmed cell death protein 1 (PD-1) blockade in a CT26 model as potent tumor microenvironment (TME) regulator."	1.72	CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. ( Chao, YS; Chen, CN; Chen, JS; Chou, CH; Chu, SH; Wu, YH; Yang, MH, 2022)
"Ovarian cancer is the leading cause of death among gynecological malignancies."	1.51	Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway. ( Deng, L; Feng, D; Liang, H; Liang, J; Ling, B; Yan, K; Zhang, X, 2019)
"We established two docetaxel‑resistant prostate cancer cell lines, PC3/DR and DU145/DR, by culturing PC3 and DU145 cells in docetaxel in a dose‑escalating manner."	1.48	Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. ( Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG, 2018)
"L1CAM was highly expressed in pancreatic cancer tissue and positively correlated with age, TNM staging and tumor differentiation."	1.48	Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. ( Hong, Y; Liu, N; Liu, Z; Ma, M; Qiu, X; Sheng, X; Tang, B; Xiong, S; Yang, D; Zhou, K; Zuo, C, 2018)
"An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has recently emerged from clinical and animal studies."	1.46	Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea. ( Almendros, I; Campillo, N; Farré, R; Gozal, D; Montserrat, JM; Navajas, D; Nonaka, PN; Picado, C; Roca-Ferrer, J; Torres, M; Vilaseca, A, 2017)
"Human pancreatic cancer cell line PANC-1 cells were treated with diverse concentrations of celecoxib (20, 60, 100 μmol/L)."	1.42	Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells. ( Gu, Z; Li, J; Li, S; Sun, K; Xiao, Z; Zhou, T, 2015)
"Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies."	1.40	Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. ( Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J, 2014)
"Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied."	1.40	Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014)
"Cetuximab in combination with celecoxib can synergistically inhibit the growth of A549 cells and downregulate the expression of KDR and AQP1 in A549 cells."	1.39	[Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer]. ( Bai, H; Wang, C; Xia, H; Ye, J, 2013)
"pylori-induced gastric cancer cell motility and invasion."	1.39	Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism. ( Fan, L; Fang, D; Guo, GJ; Lan, C; Wan, S; Wang, J; Wang, R; Yang, L; Yang, S; Zhang, Y, 2013)
"The prognosis of breast cancer in young women is influenced by reproductive history."	1.37	Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. ( Borges, VF; Conklin, MW; Eliceiri, KW; Keely, PJ; Lyons, TR; Marusyk, A; O'Brien, J; Schedin, P; Tan, AC, 2011)
"Melanoma is the most serious type of skin disease and a leading cause of death from skin disease due to its highly metastatic ability."	1.37	Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. ( Katiyar, SK; Singh, T, 2011)
"Celecoxib could inhibit PGE2 production of Tca8113 cell in a dose-dependent manner, down-regulate MMP-2 secretion of Tca8113 cell, and at the same time significantly inhibit invasion and adhesion ability of these cells."	1.36	Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. ( Huo, QJ; Li, WZ; Wang, XY; Xu, F, 2010)
"Celecoxib treatment resulted in a significant reduction in the proliferation of H."	1.35	Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. ( Chang, LL; Hu, HM; Jan, CM; Kuo, CH; Tsai, PY; Wang, JY; Wang, WM; Wu, DC; Wu, IC; Yang, SF, 2009)
"Therefore, two clones of a human colon cancer cell line (HT-29) in which GPx2 was stably knocked down by small interfering RNA (siRNA; siGPx2) were used to test whether cancer-relevant processes are affected by GPx2."	1.35	Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice. ( Banning, A; Brigelius-Flohé, R; Florian, S; Kipp, A; Krehl, S; Löwinger, M; Schmitmeier, S; Steinberg, P; Thalmann, S; Thierbach, R, 2008)
"Tumor invasion into adjacent organs and metastasis were not observed in the DMAPT/celecoxib treatment groups."	1.35	Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. ( Crooks, PA; Holcomb, B; Neelakantan, S; Njoku, V; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yip-Schneider, MT, 2008)
"Osteosarcoma is the most common primary bone tumor, but the pathogenesis is not well understood."	1.34	Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. ( Choe, M; Choi, EM; Ha, KS; Han, JA; Kim, H; Kim, JI; Kim, SR; Kim, SS; Kim, YM; Lee, EJ; Park, JH, 2007)
"Thalidomide has been shown to have antiangiogenic and immunomodulatory effects, including the inhibition of vascular endothelial growth factor, basic fibroblast growth factor and tumor necrosis factor alpha."	1.33	[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. ( Hada, M; Horiuchi, T; Shinji, H, 2006)
"Amiloride is an effective plasminogen activator inhibitor, while celecoxib is a cylcooxygenase-2 inhibitor."	1.32	Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. ( Evans, DM; Sloan Stakleff, KD, 2004)

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.27)	18.2507
2000's	13 (29.55)	29.6817
2010's	29 (65.91)	24.3611
2020's	1 (2.27)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

1 (2.27)

18.2507

2000's

13 (29.55)

29.6817

2010's

29 (65.91)

24.3611

2020's

1 (2.27)

2.80

Authors

Authors	Studies
Chen, JS	1
Chou, CH	1
Wu, YH	1
Yang, MH	1
Chu, SH	1
Chao, YS	1
Chen, CN	1
Benelli, R	1
Barboro, P	1
Costa, D	1
Astigiano, S	1
Barbieri, O	1
Capaia, M	1
Poggi, A	1
Ferrari, N	1
Zhang, X	1
Yan, K	1
Deng, L	1
Liang, J	1
Liang, H	1
Feng, D	1
Ling, B	1
Ko, CJ	1
Lan, SW	1
Lu, YC	1
Cheng, TS	1
Lai, PF	1
Tsai, CH	1
Hsu, TW	1
Lin, HY	1
Shyu, HY	1
Wu, SR	1
Lin, HH	1
Hsiao, PW	1
Chen, CH	1
Huang, HP	1
Lee, MS	1
Zuo, C	1
Hong, Y	1
Qiu, X	1
Yang, D	1
Liu, N	1
Sheng, X	1
Zhou, K	1
Tang, B	1
Xiong, S	1
Ma, M	1
Liu, Z	1
Lin, JZ	1
Hameed, I	1
Xu, Z	1
Yu, Y	1
Ren, ZY	1
Zhu, JG	1
Liu, X	1
Wu, Y	1
Zhou, Z	1
Huang, M	1
Deng, W	1
Wang, Y	1
Zhou, X	1
Chen, L	1
Li, Y	2
Zeng, T	1
Wang, G	1
Fu, B	1
Lan, C	1
Yang, L	1
Fan, L	1
Zhang, Y	2
Wang, J	1
Guo, GJ	1
Wan, S	1
Yang, S	1
Wang, R	1
Fang, D	1
Bhattacharya, A	1
Shi, Y	1
Xia, H	1
Ye, J	1
Bai, H	1
Wang, C	1
Yusup, G	1
Akutsu, Y	1
Mutallip, M	1
Qin, W	2
Hu, X	1
Komatsu-Akimoto, A	1
Hoshino, I	1
Hanari, N	1
Mori, M	1
Akanuma, N	1
Isozaki, Y	1
Matsubara, H	1
Blazeby, JM	1
Hall, E	1
Aaronson, NK	1
Lloyd, L	1
Waters, R	1
Kelly, JD	1
Fayers, P	1
Li, WW	1
Long, GX	1
Liu, DB	1
Mei, Q	1
Wang, JF	1
Hu, GY	1
Jiang, JZ	1
Sun, W	1
Gan, L	1
Hu, GQ	1
Xu, K	1
Wang, L	1
Shu, HK	1
Ju, RJ	1
Li, XT	1
Shi, JF	1
Li, XY	1
Sun, MG	1
Zeng, F	1
Zhou, J	1
Liu, L	1
Zhang, CX	1
Zhao, WY	1
Lu, WL	1
Tong, H	1
Li, X	1
Wei, B	1
Tang, C	1
Li, S	1
Gu, Z	1
Xiao, Z	1
Zhou, T	1
Li, J	1
Sun, K	1
Cha, BK	1
Kim, YS	1
Hwang, KE	1
Cho, KH	1
Oh, SH	1
Kim, BR	1
Jun, HY	1
Yoon, KH	1
Jeong, ET	1
Kim, HR	1
Campillo, N	1
Torres, M	1
Vilaseca, A	1
Nonaka, PN	1
Gozal, D	1
Roca-Ferrer, J	1
Picado, C	1
Montserrat, JM	1
Farré, R	1
Navajas, D	1
Almendros, I	1
Yip-Schneider, MT	1
Wu, H	1
Njoku, V	1
Ralstin, M	1
Holcomb, B	1
Crooks, PA	1
Neelakantan, S	1
Sweeney, CJ	1
Schmidt, CM	1
Banning, A	1
Kipp, A	1
Schmitmeier, S	1
Löwinger, M	1
Florian, S	1
Krehl, S	1
Thalmann, S	1
Thierbach, R	1
Steinberg, P	1
Brigelius-Flohé, R	1
Namba, T	1
Homan, T	1
Nishimura, T	1
Mima, S	1
Hoshino, T	1
Mizushima, T	1
Kuo, CH	1
Hu, HM	1
Tsai, PY	1
Wu, IC	1
Yang, SF	1
Chang, LL	1
Wang, JY	1
Jan, CM	1
Wang, WM	1
Wu, DC	1
Kim, YY	1
Lee, EJ	3
Kim, YK	1
Kim, SM	1
Park, JY	1
Myoung, H	1
Kim, MJ	1
Dhawan, D	1
Craig, BA	1
Cheng, L	1
Snyder, PW	1
Mohammed, SI	1
Stewart, JC	1
Zheng, R	1
Loman, RA	1
Foster, RS	1
Knapp, DW	1
Pierga, JY	1
Delaloge, S	1
Espié, M	1
Brain, E	1
Sigal-Zafrani, B	1
Mathieu, MC	1
Bertheau, P	1
Guinebretière, JM	1
Spielmann, M	1
Savignoni, A	1
Marty, M	1
Li, WZ	1
Huo, QJ	1
Wang, XY	1
Xu, F	1
Bocca, C	1
Bozzo, F	1
Bassignana, A	1
Miglietta, A	1
Lustberg, MB	1
Povoski, SP	1
Zhao, W	1
Ziegler, RM	1
Sugimoto, Y	1
Ruppert, AS	1
Lehman, AM	1
Shiels, DR	1
Mrozek, E	1
Ramaswamy, B	1
Layman, RM	1
Brueggemeier, RW	1
Shapiro, CL	1
Lyons, TR	1
O'Brien, J	1
Borges, VF	1
Conklin, MW	1
Keely, PJ	1
Eliceiri, KW	1
Marusyk, A	1
Tan, AC	1
Schedin, P	1
Sabichi, AL	1
Lee, JJ	1
Grossman, HB	1
Liu, S	1
Richmond, E	1
Czerniak, BA	1
De la Cerda, J	1
Eagle, C	1
Viner, JL	1
Palmer, JL	1
Lerner, SP	1
Singh, T	1
Katiyar, SK	1
Barlow, M	1
Edelman, M	1
Glick, RD	1
Steinberg, BM	1
Soffer, SZ	1
Chow, LW	1
Tung, SY	1
Ng, TY	1
Im, SA	1
Lee, MH	1
Yip, AY	1
Toi, M	1
Glück, S	1
Fu, SL	1
Wu, YL	1
Zhang, YP	1
Qiao, MM	1
Chen, Y	1
Prosperi, JR	1
Mallery, SR	1
Kigerl, KA	1
Erfurt, AA	1
Robertson, FM	1
Evans, DM	1
Sloan Stakleff, KD	1
Xiong, HQ	1
Plunkett, W	1
Wolff, R	1
Du, M	1
Lenzi, R	1
Abbruzzese, JL	1
Basu, GD	1
Pathangey, LB	1
Tinder, TL	1
Gendler, SJ	1
Mukherjee, P	1
Hada, M	1
Horiuchi, T	1
Shinji, H	1
Kwak, YE	1
Jeon, NK	1
Kim, J	1
Choi, EM	1
Kim, SR	1
Park, JH	1
Kim, H	1
Ha, KS	1
Kim, YM	1
Kim, SS	1
Choe, M	1
Kim, JI	1
Han, JA	1
Sauter, ER	1
Hewett, JE	1
Ruhlen, RL	1
Flynn, JT	1
Rottinghaus, G	1
Chen, YC	1
Ziegler, J	1

Studies

Chen, JS

Chou, CH

Wu, YH

Yang, MH

Chu, SH

Chao, YS

Chen, CN

Benelli, R

Barboro, P

Costa, D

Astigiano, S

Barbieri, O

Capaia, M

Poggi, A

Ferrari, N

Zhang, X

Yan, K

Deng, L

Liang, J

Liang, H

Feng, D

Ling, B

Ko, CJ

Lan, SW

Lu, YC

Cheng, TS

Lai, PF

Tsai, CH

Hsu, TW

Lin, HY

Shyu, HY

Wu, SR

Lin, HH

Hsiao, PW

Chen, CH

Huang, HP

Lee, MS

Zuo, C

Hong, Y

Qiu, X

Yang, D

Liu, N

Sheng, X

Zhou, K

Tang, B

Xiong, S

Ma, M

Liu, Z

Lin, JZ

Hameed, I

Xu, Z

Yu, Y

Ren, ZY

Zhu, JG

Liu, X

Wu, Y

Zhou, Z

Huang, M

Deng, W

Wang, Y

Zhou, X

Chen, L

Li, Y

Zeng, T

Wang, G

Fu, B

Lan, C

Yang, L

Fan, L

Zhang, Y

Wang, J

Guo, GJ

Wan, S

Yang, S

Wang, R

Fang, D

Bhattacharya, A

Shi, Y

Xia, H

Ye, J

Bai, H

Wang, C

Yusup, G

Akutsu, Y

Mutallip, M

Qin, W

Hu, X

Komatsu-Akimoto, A

Hoshino, I

Hanari, N

Mori, M

Akanuma, N

Isozaki, Y

Matsubara, H

Blazeby, JM

Hall, E

Aaronson, NK

Lloyd, L

Waters, R

Kelly, JD

Fayers, P

Li, WW

Long, GX

Liu, DB

Mei, Q

Wang, JF

Hu, GY

Jiang, JZ

Sun, W

Gan, L

Hu, GQ

Xu, K

Wang, L

Shu, HK

Ju, RJ

Li, XT

Shi, JF

Li, XY

Sun, MG

Zeng, F

Zhou, J

Liu, L

Zhang, CX

Zhao, WY

Lu, WL

Tong, H

Li, X

Wei, B

Tang, C

Li, S

Gu, Z

Xiao, Z

Zhou, T

Li, J

Sun, K

Cha, BK

Kim, YS

Hwang, KE

Cho, KH

Oh, SH

Kim, BR

Jun, HY

Yoon, KH

Jeong, ET

Kim, HR

Campillo, N

Torres, M

Vilaseca, A

Nonaka, PN

Gozal, D

Roca-Ferrer, J

Picado, C

Montserrat, JM

Farré, R

Navajas, D

Almendros, I

Yip-Schneider, MT

Wu, H

Njoku, V

Ralstin, M

Holcomb, B

Crooks, PA

Neelakantan, S

Sweeney, CJ

Schmidt, CM

Banning, A

Kipp, A

Schmitmeier, S

Löwinger, M

Florian, S

Krehl, S

Thalmann, S

Thierbach, R

Steinberg, P

Brigelius-Flohé, R

Namba, T

Homan, T

Nishimura, T

Mima, S

Hoshino, T

Mizushima, T

Kuo, CH

Hu, HM

Tsai, PY

Wu, IC

Yang, SF

Chang, LL

Wang, JY

Jan, CM

Wang, WM

Wu, DC

Kim, YY

Lee, EJ

Kim, YK

Kim, SM

Park, JY

Myoung, H

Kim, MJ

Dhawan, D

Craig, BA

Cheng, L

Snyder, PW

Mohammed, SI

Stewart, JC

Zheng, R

Loman, RA

Foster, RS

Knapp, DW

Pierga, JY

Delaloge, S

Espié, M

Brain, E

Sigal-Zafrani, B

Mathieu, MC

Bertheau, P

Guinebretière, JM

Spielmann, M

Savignoni, A

Marty, M

Li, WZ

Huo, QJ

Wang, XY

Xu, F

Bocca, C

Bozzo, F

Bassignana, A

Miglietta, A

Lustberg, MB

Povoski, SP

Zhao, W

Ziegler, RM

Sugimoto, Y

Ruppert, AS

Lehman, AM

Shiels, DR

Mrozek, E

Ramaswamy, B

Layman, RM

Brueggemeier, RW

Shapiro, CL

Lyons, TR

O'Brien, J

Borges, VF

Conklin, MW

Keely, PJ

Eliceiri, KW

Marusyk, A

Tan, AC

Schedin, P

Sabichi, AL

Lee, JJ

Grossman, HB

Liu, S

Richmond, E

Czerniak, BA

De la Cerda, J

Eagle, C

Viner, JL

Palmer, JL

Lerner, SP

Singh, T

Katiyar, SK

Barlow, M

Edelman, M

Glick, RD

Steinberg, BM

Soffer, SZ

Chow, LW

Tung, SY

Ng, TY

Im, SA

Lee, MH

Yip, AY

Toi, M

Glück, S

Fu, SL

Wu, YL

Zhang, YP

Qiao, MM

Chen, Y

Prosperi, JR

Mallery, SR

Kigerl, KA

Erfurt, AA

Robertson, FM

Evans, DM

Sloan Stakleff, KD

Xiong, HQ

Plunkett, W

Wolff, R

Du, M

Lenzi, R

Abbruzzese, JL

Basu, GD

Pathangey, LB

Tinder, TL

Gendler, SJ

Mukherjee, P

Hada, M

Horiuchi, T

Shinji, H

Kwak, YE

Jeon, NK

Kim, J

Choi, EM

Kim, SR

Park, JH

Kim, H

Ha, KS

Kim, YM

Kim, SS

Choe, M

Kim, JI

Han, JA

Sauter, ER

Hewett, JE

Ruhlen, RL

Flynn, JT

Rottinghaus, G

Chen, YC

Ziegler, J

Trial	Phase	Enrollment	Study Type	Start Date	Status
Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493]	Phase 3	200 participants (Anticipated)	Interventional	2017-06-02	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493]

Phase 3

200 participants (Anticipated)

Interventional

2017-06-02

Recruiting

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. European urology, 2014, Volume: 66, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anxiety; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhi	2014
Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Molecular cancer therapeutics, 2010, Volume: 9, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio	2010
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast cancer research and treatment, 2010, Volume: 122, Issue:2 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com	2010
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clinical breast cancer, 2011, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular	2011
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:10 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Male	2011
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide	2013
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administ	2005
Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. BMC cancer, 2008, Feb-11, Volume: 8 Topics: Adult; Aged; Aged, 80 and over; Body Fluids; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors;	2008

Article

Year

Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer.

European urology, 2014, Volume: 66, Issue:6

Topics: Adult; Aged; Aged, 80 and over; Anxiety; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhi

2014

Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.

Molecular cancer therapeutics, 2010, Volume: 9, Issue:5

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

2010

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.

Breast cancer research and treatment, 2010, Volume: 122, Issue:2

Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010

Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Clinical breast cancer, 2011, Volume: 11, Issue:4

Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular

2011

A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:10

Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Male

2011

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.

Expert opinion on investigational drugs, 2013, Volume: 22, Issue:3

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide

2013

A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.

Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:6

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administ

2005

Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women.

BMC cancer, 2008, Feb-11, Volume: 8

Topics: Adult; Aged; Aged, 80 and over; Body Fluids; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors;

2008

Article	Year
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. Scientific reports, 2022, 01-20, Volume: 12, Issue:1 Topics: Adenocarcinoma; Aminopyridines; Animals; Antibodies, Monoclonal; Benzamides; Celecoxib; Cell Line, T	2022
Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer. International journal of molecular sciences, 2019, Dec-03, Volume: 20, Issue:23 Topics: Amphiregulin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Li	2019
Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway. Cell transplantation, 2019, Volume: 28, Issue:1_suppl Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell	2019
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. Oncogene, 2017, 08-10, Volume: 36, Issue:32 Topics: Animals; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HEK2	2017
Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2018, Volume: 18, Issue:3 Topics: CD56 Antigen; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Down-Reg	2018
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. Oncology reports, 2018, Volume: 40, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Ce	2018
Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. International journal of molecular medicine, 2019, Volume: 44, Issue:2 Topics: Antineoplastic Agents; Celecoxib; Cell Line; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Epitheli	2019
Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism. Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:8 Topics: Anoikis; Celecoxib; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors;	2013
Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. Carcinogenesis, 2013, Volume: 34, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caspases; Celecoxib; Cel	2013
[Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013, Volume: 16, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto	2013
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. International journal of oncology, 2014, Volume: 44, Issue:4 Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C	2014
Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Die Pharmazie, 2014, Volume: 69, Issue:2 Topics: Carcinoma; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coloring Agents; Cyclooxy	2014
COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget, 2014, Mar-15, Volume: 5, Issue:5 Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygen	2014
Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials, 2014, Volume: 35, Issue:26 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Dr	2014
Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celecoxib; Chemoembolizat	2015
Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenas	2015
Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget, 2016, Aug-30, Volume: 7, Issue:35 Topics: A549 Cells; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols;	2016
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea. Scientific reports, 2017, 03-16, Volume: 7 Topics: Animals; Celecoxib; Cell Polarity; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Model	2017
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas, 2008, Volume: 37, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Chemokines,	2008
Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice. Cancer research, 2008, Dec-01, Volume: 68, Issue:23 Topics: Adenocarcinoma; Animals; Celecoxib; Cell Growth Processes; Cell Movement; Colonic Neoplasms; Cycloox	2008
Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects. The Journal of biological chemistry, 2009, Feb-13, Volume: 284, Issue:7 Topics: Activating Transcription Factor 4; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Ste	2009
Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World journal of gastroenterology, 2009, Oct-21, Volume: 15, Issue:39 Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Celecoxib; Cell Proliferation; Cyclooxygenase 2; C	2009
Anti-cancer effects of celecoxib in head and neck carcinoma. Molecules and cells, 2010, Feb-28, Volume: 29, Issue:2 Topics: Animals; Celecoxib; Cell Death; Cell Line, Tumor; Chemoprevention; Cricetinae; Cyclooxygenase 2; Cyc	2010
Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. Prostaglandins & other lipid mediators, 2010, Volume: 93, Issue:3-4 Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygena	2010
Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Molecular and cellular biochemistry, 2011, Volume: 350, Issue:1-2 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cell	2011
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature medicine, 2011, Aug-07, Volume: 17, Issue:9 Topics: Analysis of Variance; Animals; Blotting, Western; Breast Neoplasms; Carcinoma, Ductal; Celecoxib; Ce	2011
Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PloS one, 2011, Volume: 6, Issue:10 Topics: Catechin; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cyclooxygenase 2; Cyclooxygenase	2011
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. Journal of pediatric surgery, 2012, Volume: 47, Issue:6 Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc	2012
Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World journal of gastroenterology, 2004, Jul-01, Volume: 10, Issue:13 Topics: Animals; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 I	2004
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins & other lipid mediators, 2004, Volume: 73, Issue:3-4 Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Clone Cells; Collagen; Cyclooxyge	2004
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clinical & experimental metastasis, 2004, Volume: 21, Issue:4 Topics: Amiloride; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibit	2004
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast cancer research : BCR, 2005, Volume: 7, Issue:4 Topics: Animals; Breast Neoplasms; Celecoxib; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Cyclooxygena	2005
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration	2006
The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Annals of the New York Academy of Sciences, 2007, Volume: 1095 Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibito	2007
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Experimental & molecular medicine, 2007, Aug-31, Volume: 39, Issue:4 Topics: Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cy	2007
Cancer and arthritis share underlying processes. Journal of the National Cancer Institute, 1998, Jun-03, Volume: 90, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cell Transfo	1998

Article

Year

CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.

Scientific reports, 2022, 01-20, Volume: 12, Issue:1

Topics: Adenocarcinoma; Aminopyridines; Animals; Antibodies, Monoclonal; Benzamides; Celecoxib; Cell Line, T

2022

Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.

International journal of molecular sciences, 2019, Dec-03, Volume: 20, Issue:23

Topics: Amphiregulin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Li

2019

Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway.

Cell transplantation, 2019, Volume: 28, Issue:1_suppl

Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell

2019

Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.

Oncogene, 2017, 08-10, Volume: 36, Issue:32

Topics: Animals; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HEK2

2017

Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2018, Volume: 18, Issue:3

Topics: CD56 Antigen; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Down-Reg

2018

Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.

Oncology reports, 2018, Volume: 40, Issue:4

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Ce

2018

Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis.

International journal of molecular medicine, 2019, Volume: 44, Issue:2

Topics: Antineoplastic Agents; Celecoxib; Cell Line; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Epitheli

2019

Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism.

Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:8

Topics: Anoikis; Celecoxib; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors;

2013

Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination.

Carcinogenesis, 2013, Volume: 34, Issue:11

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caspases; Celecoxib; Cel

2013

[Effects of cetuximab combined with celecoxib on apoptosis and KDR and AQP1 expression in lung cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013, Volume: 16, Issue:12

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2013

A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.

International journal of oncology, 2014, Volume: 44, Issue:4

Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C

2014

Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.

Die Pharmazie, 2014, Volume: 69, Issue:2

Topics: Carcinoma; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coloring Agents; Cyclooxy

2014

COX-2 overexpression increases malignant potential of human glioma cells through Id1.

Oncotarget, 2014, Mar-15, Volume: 5, Issue:5

Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygen

2014

Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.

Biomaterials, 2014, Volume: 35, Issue:26

Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Dr

2014

Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma.

Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:5

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celecoxib; Chemoembolizat

2015

Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells.

International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:2

Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenas

2015

Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.

Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

Topics: A549 Cells; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols;

2016

Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.

Scientific reports, 2017, 03-16, Volume: 7

Topics: Animals; Celecoxib; Cell Polarity; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Model

2017

Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.

Pancreas, 2008, Volume: 37, Issue:3

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Chemokines,

2008

Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice.

Cancer research, 2008, Dec-01, Volume: 68, Issue:23

Topics: Adenocarcinoma; Animals; Celecoxib; Cell Growth Processes; Cell Movement; Colonic Neoplasms; Cycloox

2008

Up-regulation of S100P expression by non-steroidal anti-inflammatory drugs and its role in anti-tumorigenic effects.

The Journal of biological chemistry, 2009, Feb-13, Volume: 284, Issue:7

Topics: Activating Transcription Factor 4; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Ste

2009

Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.

World journal of gastroenterology, 2009, Oct-21, Volume: 15, Issue:39

Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Celecoxib; Cell Proliferation; Cyclooxygenase 2; C

2009

Anti-cancer effects of celecoxib in head and neck carcinoma.

Molecules and cells, 2010, Feb-28, Volume: 29, Issue:2

Topics: Animals; Celecoxib; Cell Death; Cell Line, Tumor; Chemoprevention; Cricetinae; Cyclooxygenase 2; Cyc

2010

Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.

Prostaglandins & other lipid mediators, 2010, Volume: 93, Issue:3-4

Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygena

2010

Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.

Molecular and cellular biochemistry, 2011, Volume: 350, Issue:1-2

Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cell

2011

Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.

Nature medicine, 2011, Aug-07, Volume: 17, Issue:9

Topics: Analysis of Variance; Animals; Blotting, Western; Breast Neoplasms; Carcinoma, Ductal; Celecoxib; Ce

2011

Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.

PloS one, 2011, Volume: 6, Issue:10

Topics: Catechin; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cyclooxygenase 2; Cyclooxygenase

2011

Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.

Journal of pediatric surgery, 2012, Volume: 47, Issue:6

Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc

2012

Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.

World journal of gastroenterology, 2004, Jul-01, Volume: 10, Issue:13

Topics: Animals; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 I

2004

Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.

Prostaglandins & other lipid mediators, 2004, Volume: 73, Issue:3-4

Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Clone Cells; Collagen; Cyclooxyge

2004

Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.

Clinical & experimental metastasis, 2004, Volume: 21, Issue:4

Topics: Amiloride; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibit

2004

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Breast cancer research : BCR, 2005, Volume: 7, Issue:4

Topics: Animals; Breast Neoplasms; Celecoxib; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Cyclooxygena

2005

[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].

Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration

2006

The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.

Annals of the New York Academy of Sciences, 2007, Volume: 1095

Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibito

2007

Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.

Experimental & molecular medicine, 2007, Aug-31, Volume: 39, Issue:4

Topics: Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cy

2007

Cancer and arthritis share underlying processes.

Journal of the National Cancer Institute, 1998, Jun-03, Volume: 90, Issue:11

Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cell Transfo

1998

celecoxib and Invasiveness, Neoplasm

Research Excerpts

Research

Studies (44)

Authors

Clinical Trials (1)

Trial Overview

Trials

Other Studies